Current Partnering Activities

  • Out-Licensing of EvitarTM (TTX 333) - Prevention of Adhesion Formation following abdominal/pelvic surgery:
    • Markets available: Japan, China, S. Korea, ASEAN, Australia, India, MENA, CIS, Russia and LATAM for EvitarTM.  The first drug shown in clinical trials to prevent adhesion formation following laparoscopic surgery.  For more information please contact us.
  • Option to license at IND or Phase 1 (build to buy) of TTX 332-Prevention of Delayed Graft Function following transplant:
    • Worldwide markets available
    • Temple will conduct preclinical and clinical work in conjunction with partner
  • Option to license at IND or Phase 1 (build to buy) of TTX 334 Oncology platform:
    • Worldwide markets available
    • Researcher and Temple team have identified chemo resistant ovarian cancer as the preferred lead indication
    • Data available in other cancers which can also be developed in conjunction with partner

Companies with a focus in the following areas would be interested in Temple's hospital and acute care portfolio:

  • Hospital and acute care
  • Oncology
  • Transplant
  • Women’s health
  • Surgery
  • Fibrosis

Our medical advisors, collaborators and researchers work at the following organizations.

  • Beth Israel
  • Brigham and Women's Hospital
  • Harvard Medical
  • Maastricht U
  • Cleveland Clinic
  • Stanford
  • moran
  • ukbb
  • u of t
  • usask
  • ucsf
  • dsm
  • evonik

MeEt Us

View our upcoming events

View All Events